IN8bio, Inc. (NASDAQ:INAB) Short Interest Update

IN8bio, Inc. (NASDAQ:INAB) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,000,000 shares, a growth of 578.4% from the October 15th total of 147,400 shares. Based on an average trading volume of 1,080,000 shares, the short-interest ratio is currently 0.9 days. Approximately 3.1% of the shares of the company are sold short.

IN8bio Trading Up 10.5 %

NASDAQ:INAB traded up $0.03 during trading hours on Thursday, reaching $0.35. 279,101 shares of the company were exchanged, compared to its average volume of 547,170. The stock has a 50 day simple moving average of $0.30 and a 200 day simple moving average of $0.68. IN8bio has a 52-week low of $0.22 and a 52-week high of $2.48. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.66 and a quick ratio of 2.66. The firm has a market cap of $16.38 million, a price-to-earnings ratio of -0.42 and a beta of -0.07.

Institutional Trading of IN8bio

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp boosted its position in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 851,280 shares of the company’s stock after purchasing an additional 251,600 shares during the period. Sigma Planning Corp owned approximately 1.82% of IN8bio worth $230,000 at the end of the most recent reporting period. 92.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their target price on shares of IN8bio from $12.50 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.